Search
Fennec Pharmaceuticals Inc
FENCAdd to Watchlist
9.570USD
-0.340-3.43%
Close 07-31 16:00（ET）Quotes delayed by 15 min
332.43MMarket Cap
LossP/E TTM
More Details of Fennec Pharmaceuticals Inc Company
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Fennec Pharmaceuticals Inc Info
Ticker SymbolFENC
Company nameFennec Pharmaceuticals Inc
IPO dateJun 05, 2001
CEOHackman (Jeffrey S)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJun 05
AddressPO Box 13628
CityRESEARCH TRIANGLE PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27709
Phone19196364530
Websitehttps://fennecpharma.com/
Ticker SymbolFENC
IPO dateJun 05, 2001
CEOHackman (Jeffrey S)
Company Executives of Fennec Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Khalid Islam, Ph.D.
Mr. Khalid Islam, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
213.82K
--
Mr. Jeffrey S. (Jeff) Hackman
Mr. Jeffrey S. (Jeff) Hackman
Chief Executive Officer, Director
Chief Executive Officer, Director
67.46K
+1.72%
Mr. Rostislav C. (Rosty) Raykov
Mr. Rostislav C. (Rosty) Raykov
Director
Director
--
--
Mr. Robert C. Andrade
Mr. Robert C. Andrade
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris A. Rallis
Mr. Chris A. Rallis
Independent Director
Independent Director
--
--
Dr. Marco Maria Brughera
Dr. Marco Maria Brughera
Independent Director
Independent Director
--
--
Dr. Jodi A. Cook
Dr. Jodi A. Cook
Independent Director
Independent Director
--
--
Dr. Pierre Sargis Sayad, Ph.D.
Dr. Pierre Sargis Sayad, Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Khalid Islam, Ph.D.
Mr. Khalid Islam, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
213.82K
--
Mr. Jeffrey S. (Jeff) Hackman
Mr. Jeffrey S. (Jeff) Hackman
Chief Executive Officer, Director
Chief Executive Officer, Director
67.46K
+1.72%
Mr. Rostislav C. (Rosty) Raykov
Mr. Rostislav C. (Rosty) Raykov
Director
Director
--
--
Mr. Robert C. Andrade
Mr. Robert C. Andrade
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Chris A. Rallis
Mr. Chris A. Rallis
Independent Director
Independent Director
--
--
Dr. Marco Maria Brughera
Dr. Marco Maria Brughera
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Fennec Pharmaceuticals Inc?
The top five shareholders of Fennec Pharmaceuticals Inc are: Mr. Khalid Islam, Ph.D.
How many institutions hold shares of Fennec Pharmaceuticals Inc (FENC)?
As of 2026Q1, 178 institutions hold shares of Fennec Pharmaceuticals Inc, with a combined market value of approximately 18.57M, accounting for 53.51% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1073677.00.